The respiratory effects of oral ethyl loflazepate in volunteers
| Autor: | G. E. Mawer, N. P. C. Randall, Barbara J. Pleuvry, E. J. Fazackerley, I. Bradbrook |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Male medicine.medical_specialty Flurazepam Metabolite Body Temperature Benzodiazepines chemistry.chemical_compound Double-Blind Method Oral administration Internal medicine Respiration medicine Humans Pharmacology (medical) Volunteer Active metabolite Ethyl loflazepate Pharmacology Benzodiazepinones Clinical Trials as Topic business.industry Hemodynamics Respiratory Function Tests Endocrinology Anti-Anxiety Agents chemistry Toxicity Female business Research Article medicine.drug |
| Zdroj: | British Journal of Clinical Pharmacology. 23:183-187 |
| ISSN: | 0306-5251 |
| DOI: | 10.1111/j.1365-2125.1987.tb03027.x |
| Popis: | A volunteer study was undertaken to assess the respiratory effects of ethyl loflazepate, a new benzodiazepine, and to correlate these with plasma concentrations of the active metabolites. Twelve volunteers were given placebo, 2 mg ethyl loflazepate, and 6 mg ethyl loflazepate on separate occasions. Respiration and plasma metabolite levels were assessed hourly for 8 h and at 24 h. The 6 mg ethyl loflazepate treatment produced a significant decrease (P less than 0.02) in the ventilatory response to carbon dioxide at 5 h. However this did not equate with a peak in plasma metabolite concentrations which were maintained at a plateau level from 4 to 24 h. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text